Kim JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, et al. Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Diabetes Obes Metab 2023 Jan 2. doi: 10.1111/dom.14965.
PMID: 36594154